Cargando…

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

BACKGROUND: A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a bendamustine-based combination regimen for the treatment of relapsed/refractory PCNSL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Therasa, Choi, He Yun, Lee, Hyun-Seo, Jung, Sung-Hoon, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Lee, Je-Jung, Yoo, Hee-Doo, Yang, Deok-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038347/ https://www.ncbi.nlm.nih.gov/pubmed/29986691 http://dx.doi.org/10.1186/s12885-018-4632-y

Ejemplares similares

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment
por: Nguyen, Hong Hanh, et al.
Publicado: (2016)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
por: Yang, Deok-Hwan, et al.
Publicado: (2015)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)
por: Gomes Candido Reis, Diego, et al.
Publicado: (2021)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2010)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
por: Bae, Soo-Young, et al.
Publicado: (2011)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Treatment outcome and prognostic factors in PCNSL
por: Niparuck, Pimjai, et al.
Publicado: (2019)

Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma
por: Kim, Mihee, et al.
Publicado: (2021)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
por: Hong, Seung-Dok, et al.
Publicado: (2011)

Next‐generation sequencing‐based analysis to assess the pattern of relapse in patients with Philadelphia‐positive acute lymphoblastic leukemia
por: Ahn, Jae‐Sook, et al.
Publicado: (2022)

P1194: PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS
por: Song, Ga-Young, et al.
Publicado: (2023)

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
por: Chu, Tan-Huy, et al.
Publicado: (2022)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
por: Lee, Seung-Shin, et al.
Publicado: (2015)

Different imaging patterns of PCNSL and IVL: a case report
por: Jeon, Seung-Ho, et al.
Publicado: (2019)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Multiple Intracranial Tuberculomas Mimicking Granulocytic Sarcomas in Acute Myeloid Leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2007)

Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors
por: Downs, Bradley M., et al.
Publicado: (2021)

Primary central nervous system lymphoma (PCNSL) mimicking a falx meningioma with increasingly massive intracerebral hemorrhage
por: Tomita, Yusuke, et al.
Publicado: (2023)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dae459g8675ut2ee7ts4vguaqu